演題抄録

一般演題 (示説)

開催概要
開催回
第54回・2016年・横浜
 

Watchful Waiting (WW) in localized prostate cancer: A single institution experience

演題番号 : P25-9

[筆頭演者]
Mermershtain Wilmosh:1 
[共同演者]
Ariad Samuel:1、Rouvinov Keren:1

1:Soroka University Medical Center, Israel・Department of Oncology・Onco - Urology Service

 

Introduction: Following widespread introduction of prostate-specific antigen (PSA) testing, prostate cancer incidence has increased dramatically. Many of these diagnoses represent clinically irrelevant tumors, and the risk of overtreatment poses a tremendous clinical and ethical dilemma.
Material and Methods: From, November 1999, through, May 2011, 61 men were assigned to WW. The median age was 69 yrs (range 57 to 81 yrs). All men were followed every 4 mts during for a clinical examination and blood tests, including PSA assay. All patients have a baseline bone scan. Repeated bone scan was obtained PSA level increases that would suggest disease progression. All patients asked about quality of life with each follow-up visit.
Results: During a median of 4.6 yrs of follow-up (range 15 mts to 9 yrs), 1 men in the WW group died (acute MI). At diagnosis, the median PSA level was 6.4ng/ml. The Gleason score (GS) distribution was as follows: 7 (11.5%) with GS-5, 52 (85%) GS-6, and 2 (3.3%) with GS-7. 9 (14.8%) repeated the biopsy. At the rate of therapy was 24.6% (15pts). and the median time from diagnosis to treatment was 36.9 mts (range from 15 to 89 mts). The treatment distribution was as follows: 9pts (14.8%) treated by radiotherapy and 6pts (9.8%) received intermittent hormonal therapy. The median PSA level at start of the treatment was 6.3ng/ml in group with received radiotherapy, and 5.6ng/ml in intermittent hormonal therapy group. The distribution of patients received treatment by age group was: <70 yrs: 7pts, 70-79 yrs: 7 pts, >80 yrs: 1pt,
Conclusion: WW is as acceptable approach for patients with low risk prostate cancer and preserves the better quality of life .

キーワード

臓器別:前立腺・男性生殖器

手法別:臨床試験

前へ戻る